Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Torticollis
- Focus Registrational; Therapeutic Use
- Acronyms ASPEN-1
- Sponsors Revance Therapeutics
- 12 Apr 2024 According to a Revance Therapeutics media release, data assessing patient-desired retreatment intervals and examining the influence of the formulation of DAXXIFY on clinical performance, will be presented at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.
- 02 Feb 2024 Results published in a Revance Therapeutics media release.
- 02 Feb 2024 According to a Revance Therapeutics media release, publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology, the medical journal of the American Academy of Neurology.